JP2010524849A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524849A5
JP2010524849A5 JP2010501126A JP2010501126A JP2010524849A5 JP 2010524849 A5 JP2010524849 A5 JP 2010524849A5 JP 2010501126 A JP2010501126 A JP 2010501126A JP 2010501126 A JP2010501126 A JP 2010501126A JP 2010524849 A5 JP2010524849 A5 JP 2010524849A5
Authority
JP
Japan
Prior art keywords
rap
cyclic
mutation
peptide
rap peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010501126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/057863 external-priority patent/WO2008116171A1/en
Publication of JP2010524849A publication Critical patent/JP2010524849A/ja
Publication of JP2010524849A5 publication Critical patent/JP2010524849A5/ja
Pending legal-status Critical Current

Links

JP2010501126A 2007-03-21 2008-03-21 環状受容体関連蛋白ペプチド Pending JP2010524849A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91923807P 2007-03-21 2007-03-21
PCT/US2008/057863 WO2008116171A1 (en) 2007-03-21 2008-03-21 Cyclic receptor-associated protein (rap) peptides

Publications (2)

Publication Number Publication Date
JP2010524849A JP2010524849A (ja) 2010-07-22
JP2010524849A5 true JP2010524849A5 (enExample) 2012-04-19

Family

ID=39591450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501126A Pending JP2010524849A (ja) 2007-03-21 2008-03-21 環状受容体関連蛋白ペプチド

Country Status (10)

Country Link
US (1) US8440629B2 (enExample)
EP (1) EP2132224B1 (enExample)
JP (1) JP2010524849A (enExample)
KR (2) KR101801454B1 (enExample)
CN (1) CN101861334A (enExample)
AT (1) ATE539089T1 (enExample)
BR (1) BRPI0809234A2 (enExample)
CA (1) CA2681522A1 (enExample)
MX (1) MX2009010148A (enExample)
WO (1) WO2008116171A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN102026667B (zh) 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
CA2757645C (en) * 2009-04-06 2018-05-15 Mayo Foundation For Medical Education And Research Methods and materials for delivering molecules
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
JP6170675B2 (ja) * 2010-01-28 2017-07-26 ラプトール ファーマシューティカルズ インコーポレイテッド 受容体関連タンパク質(rap)ペプチド−フコシダーゼ阻害薬複合体による肝障害処置のための方法
WO2011160082A2 (en) 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US20180021404A1 (en) * 2015-02-20 2018-01-25 The Regents Of The University Of California Methods and compositions for treating glaucoma
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CN109422801B (zh) * 2017-08-31 2022-07-08 复旦大学 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
WO2019108806A1 (en) * 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
CA3163139A1 (en) * 2018-12-27 2020-07-02 Vivienne I. Rebel Compositions and methods for treating cancer
US11572394B2 (en) * 2020-02-16 2023-02-07 Pasteur Institute Of Iran Peptides for targeting LRP6-overexpressed cells
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
CN116286380B (zh) * 2021-12-21 2026-01-09 暨南大学 环五肽类化合物及其在α-糖苷酶抑制剂类降糖药物或预防保健品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
IT1122765B (it) * 1978-11-06 1986-04-23 Srm Hydromekanik Ab Frizione a dischi multipli
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) * 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6238908B1 (en) * 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
EP0893949B1 (en) * 1996-01-16 2005-04-27 Ronald J. Sokol Use of antioxidant agents to treat cholestatic liver disease
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) * 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6261595B1 (en) * 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6596762B2 (en) * 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
WO2005002515A2 (en) * 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8877714B2 (en) * 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
JP2010503710A (ja) * 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質(rap)結合体の投与による肝障害の処置

Similar Documents

Publication Publication Date Title
Liu et al. D‐peptides as recognition molecules and therapeutic agents
KR101617790B1 (ko) 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
US7138105B2 (en) Compositions for delivery of therapeutics and other materials, and methods of making and using the same
IL321500A (en) Pre-stabilized hmpv f proteins
TWI886164B (zh) 1價ccap生成物之製造方法
US20170007669A1 (en) Peptide-mediated delivery of active agents across the blood-brain barrier
JP7678654B2 (ja) 複合体及びその使用
JP2009502135A5 (enExample)
US12465646B2 (en) Linkers
JP2017529059A5 (enExample)
JP7674031B2 (ja) 細胞透過性ペプチド
BRPI0620806A2 (pt) peptìdeos úteis como peptìdeos de penetração de célula
JP2015509097A5 (enExample)
JP2010507391A (ja) 組織傷害の修復におけるストロマ細胞由来因子1のプロテアーゼ耐性変異体
AU2021202789A1 (en) Cancer immunotherapeutic
US20150252081A1 (en) Methods and compositions for controlling assembly of viral proteins
JP2003514852A (ja) 炎症反応を阻害する細胞透過性ペプチドおよび使用方法
JP2009508494A5 (enExample)
US20200131231A1 (en) Cell penetrating peptides
JP2022118184A (ja) コンジュゲートされたc1エステラーゼインヒビター及びその使用
JP2025166082A (ja) 分子ガイドシステムペプチド及びその使用
JP7766489B2 (ja) 免疫調節特性を有するペプチド
US10072065B2 (en) Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
EP4577229A1 (en) Brain penetrating peptides and methods of use thereof
CN119744169A (zh) 用于靶向中枢神经系统的缀合物